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Backgrounds: Contextual factors (CFs) have been recently proposed as triggers of 
placebo and nocebo effects in musculoskeletal pain. CFs encompass the features of the 
clinician (e.g. uniform), patient (e.g. expectations), patient–clinician relationship (e.g. verbal 
communication), treatment (e.g. overt therapy), and healthcare setting (e.g. design). To 
date, the researchers’ understanding of Italian patients’ knowledge about the role of CFs 
in musculoskeletal pain is lacking.
Objectives: The aim of this study was to investigate attitudes and beliefs of Italian patients 
with musculoskeletal pain about the use of CFs in clinical practice.
Methods: A national sample of Italian patients with musculoskeletal pain was recruited 
from 12 outpatient private clinics in Italy. An invitation to participate in an online survey was 
sent to patients: a) exhibiting musculoskeletal pain; b) aged 18–75; c) with a valid e-mail 
account; and d) understanding Italian language. Survey Monkey software was used to 
deliver the survey. The questionnaire was self-reported and included 17 questions and 
2 clinical vignettes on the patients’ behavior, beliefs, and attitudes towards the adoption 
of CFs in clinical practice. Descriptive statistics and frequencies described the actual 
number of respondents to each question.
Results: One thousand one hundred twelve patients participated in the survey. Five 
hundred seventy-four participants were female (52%). The average age of patients was 
41.7 ± 15.2 years. Patients defined CFs as an intervention with an unspecific effect 
(64.3%), but they believed in their clinical effectiveness. They identified several therapeutic 
effects of CFs for different health problems. Their use was considered ethically acceptable 
when it exerts beneficial psychological effects (60.4%), but it was banned if considered 
deceptive (51.1%). During clinical practice, patients wanted to be informed about the use 
of CFs (46.0%) that are accepted as an addition to other interventions to optimize clinical 
responses (39.3%). Moreover, patients explained the power of CFs through body–mind 
connections (37.1%).
Contextual Factors and Musculoskeletal PainRossettini et al.
2 July 2019 | Volume 10 | Article 478Frontiers in Psychiatry | www.frontiersin.org
Conclusion: Patients with musculoskeletal pain had positive attitudes towards the use 
and effectiveness of CFs when associated with evidence-based therapy. They mostly 
perceived the adoption of CFs in clinical practice as ethical.
Keywords: placebo effect, nocebo effect, pain, musculoskeletal, survey, conditioning, learning, expectation
INTRODUCTION
Placebo and nocebo effects represent an emerging area of interest 
in musculoskeletal treatment. In this field, for several years, 
researchers have considered placebo and nocebo as incidental 
elements to be supervised in randomized controlled trials aimed 
at isolating the specific effect of a treatment (1). However, in 
the last decades, the modern neurobiological perspective has 
conceptualized placebo and nocebo effects as results of the 
psychosocial context surrounding every healthcare intervention, 
capable of influencing patients’ pain (2).
Placebo effects are the beneficial result of a patient’s exposure to a 
positive context (3), while nocebo effects are adverse consequences 
of a patient’s interaction with a negative context (4). Expectations and 
conditioning are the main psychological mechanisms underlying 
placebo and nocebo effects, although social learning and mindset 
theories have also been demonstrated as explanations of their existing 
and their functioning (5–7). From a neurobiological perspective, the 
release of specific neurotransmitters is associated with the exposure 
to specific contexts: endogenous opioids, dopamine, cannabinoids, 
oxytocin, and vasopressin have been observed in positive contexts, 
while opioid and dopamine deactivation and cholecystokinin and 
cyclooxygenase-prostaglandins activation were observed in negative 
contexts (8–11). Moreover, different contexts can modulate neural 
pathways involved in the descending control of pain, influencing the 
activity of anterior cingulate cortex, dorsolateral prefrontal cortex, 
periaqueductal grey, and spinal cord (12–16).
The context is composed of several therapeutic signs, 
symbols, metaphors, and healing rituals (17, 18), called 
Contextual Factors (CFs), that inform the patients on the value 
and the meaning of treatment delivered and can influence their 
healthcare experience by triggering placebo and nocebo effects 
(19). The therapeutic encounter is strongly characterized by CFs 
such as a) the clinicians’ beliefs and behaviors; b) the patients’ 
expectations and his/her previous experiences; c) the colour 
and the shape of the intervention; d) the verbal and non-verbal 
element of communication; and e) the ornaments and the colour 
of the healthcare setting (2). A robust body of evidence informs 
clinicians about the positive impact of CFs on therapeutic 
outcomes such as pain, disability, satisfaction, and perceived 
quality in different healthcare field as medicine, nursing, 
physiotherapy, musculoskeletal, and neurological rehabilitation 
(2, 20–23). As a consequence, a recent experts consensus 
suggested the adoption of CFs to stimulate placebo effects and to 
avoid nocebo effects, thus increasing the overall effectiveness of 
established evidence-based interventions (24).
From a clinical perspective, the patient’s point of view about 
CFs has been proposed as a central line of investigation (25). Up to 
now, qualitative and quantitative researches have investigated the 
participants’ point of view towards placebo using focus groups (26, 
27), interviews (28–30), and surveys (31–39–44). Studies have been 
performed in different countries such as the US (28, 29, 32–33, 34, 
38, 39), Asia (27, 42, 43), Australia (36), and Europe (26, 30, 31, 35, 
37, 40, 41, 44), involving healthy subjects (26, 27, 32, 34, 41–43) and 
patients with acute/chronic health conditions (30, 36–39, 40, 44), 
depression (43), irritable bowel syndrome (28, 29), and rheumatic 
and musculoskeletal pain (31, 33, 35). Overall, findings revealed a) a 
heterogeneous understanding of placebo effects, ranging from limited 
(27, 32, 33, 35, 36, 40) to well-expressed knowledge (30, 31, 37, 39); b) a 
dualistic conceptualization of placebo effects, as a beneficial element 
to be legitimized or as ineffective (26, 28); and c) an open vision about 
placebos in clinical practice, revealing the deception and the lack of 
informed consent as major ethical issues of their use (27, 30, 32–38, 
39, 44). However, the cultural differences and the various adopted 
definitions of “placebo treatment” threatened the development of 
a coherent body of evidence and require more research in the field 
(25, 39), particularly in Italy, where no studies  have investigated 
the attitudes and beliefs of Italian patients towards CFs.
Moreover, among other different chronic conditions greatly 
affecting the quality of life of patients, musculoskeletal pain 
medicine represents an interesting and open field of investigation, 
given its high frequency and its pervasion by CFs (2). Aligned with 
this vision, the aims of our study were to explore: a) the clinical 
behaviors, b) the definition, c) the beliefs, d) the ethical concerning, 
e) the communication implications, f) the circumstances of 
application, and g) the mechanism of actions of CFs in a nationwide 
sample of Italian patients with musculoskeletal pain.
MATERIALS AND METHODS
Design
A quantitative web-based cross-sectional survey herein reported 
in accordance with the Checklist for Reporting Results of Internet 
E-Surveys (CHERRIES) guidelines (45) and STrengthening the 
Reporting of OBservational Studies in Epidemiology (STROBE) 
(46) was performed. The Liguria Clinical Experimental Ethics 
Committee (P.R.236REG2016, accepted on 19/07/2016) approved 
the present study.
Participants and Setting
A national sample of Italian patients with musculoskeletal pain 
was recruited from 12 outpatients’ private clinics located in 
different regions of Italy (North, n = 4; Centre, n = 4; South, 
n = 4) between May and August 2018.
Abbreviations: CFs, Contextual Factors; EQI, EuroQol Index; CHERRIES, 
Checklist for Reporting Results of Internet E-Surveys; STROBE, STrengthening 
the Reporting of OBservational Studies in Epidemiology.
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Managers of each clinic provided the list of patients recruited 
for this survey to the principal investigator. The patients 
were included/excluded in accordance with  the physician’s 
judgement based on the defined criteria. The inclusion criteria 
were as follows: a) age between 18 and 75 (38, 39); b) being 
currently affected by musculoskeletal pain due to either acute 
traumatic events (e.g., a fracture) or chronic complaints 
(e.g., overuse) (47); c) having a valid e-mail account; d) good 
understanding of the Italian language (33); and e) a EuroQol 
Index (EQI) < 1. The EQI has values ranging from 0 (worst) 
to 1 (best) and was calculated using the specific normative 
data of the Italian population (48). The EQI was calculated 
starting from the answers given in the EuroQol 5-dimensional 
scale (EQ-5D-3L), that is, a descriptive system composed of 
five closed three-level single answer questions, exploring 
mobility, self-care, usual activities, pain/discomfort, and 
anxiety/depression domains. Patients affected by cancer or by 
non-musculoskeletal cause of pain (e.g. neuropathic pain) (33) 
were excluded.
The number of eligible people who responded to the survey 
was 1,112. With this sample size, a relative standard error of 3% 
of the true estimate in the population with a 95% confidence 
level within 0.03 percentage points was expected, using a simple 
random sampling approach and with the population proportion 
set to 50% (49).
Questionnaire Development 
and Pre-Testing
A survey instrument which included questions and clinical 
vignettes was developed adapting a previous survey on CFs 
performed among Italian physical therapists and nursing by our 
research group (50, 51). Questions and clinical vignettes were 
linguistically adapted to facilitate patient’s understanding and 
answers by the research group. In the whole questionnaire, the 
word “placebo” was avoided preferring the word “contextual 
factors” aimed at improving the number of responses by 
participants (26, 50–52).
The initial list was composed of 22 questions and 2 clinical 
vignettes that were critically appraised for face and content 
validity (53) using a panel of seven experts with a wide 
experience in placebo and survey design (a psychologist, a 
nurse, and five physical therapists). The experts checked the 
list independently providing feedback on content accuracy, 
relevance, wording clarity, and survey structure. Following 
the feedback received, some adjustments were made and the 
number of questions was reduced from 22 to 17 because there 
were overlapping and redundancy.
Once consensus on the final questionnaire was reached among 
the experts, a preliminary version of the survey, composed of 17 
questions and 2 clinical vignettes, was piloted in a convenience 
sample of 45 patients with musculoskeletal pain and coming 
from different Italian regions (North, n = 15, Centre, n = 15; 
South, n = 15) (54).
After the pilot, a telephone debriefing session was performed 
(53). Experts interviewed the convenience sample of patients 
about the possible problems encountered during the survey 
(e.g. recognizing questions that needed additional explanation, 
wording that was hard to read or that participants found unclear). 
The outcome of the pilot phase offered the opportunity to reword 
three items (regarding ethics, communication, and mechanism 
of action) and to improve the readability of the entire survey.
Questionnaire Implementation
The self-administered questionnaire (Supplementary file 
1 – English version, Supplementary file 2 – Italian version) 
adopted in this study was divided into three sections (A, B, 
C), which used both open-ended and closed multiple-choice 
questions (55).
Section A investigated the socio-demographic variables 
using six questions (age, sex, geographical region, social status, 
workplace, and education). Three closed multiple-choice single 
answer questions explored the features of musculoskeletal pain 
(anatomical location, time of onset, and intensity using Numeric 
Rating Scale 0–10) (56).
In Section B, two clinical vignettes were presented as two 
closed multiple-choice questions with, respectively, single and 
multiple answers:
 1) the first vignette was about the use of massage in a patient 
with low back pain and high expectations towards this 
treatment based on previous positive experience. Participant 
were asked to choose what they considered the best action 
in this situation in which the clinician knew that massage 
was not indicated and that the low back pain would have 
spontaneously disappeared in a short time;
 2) the second vignette described a clinical case of patient with 
shoulder pain who responded positively when a sham laser 
(with power-off) replaced the active laser therapy. In this 
scenario, participants were asked to draw a conclusion about 
the efficacy and effectiveness of the sham laser.
Section C comprised eight closed questions. Three closed 
multiple-choice single answer questions investigated the 
definition of CFs (“How would you define the therapeutic 
role of CFs?”), the participants’ CFs belief (Likert from 0 “not 
at all” to 4 “a lot of ”), and the potential beneficial effects of 
CFs (“What are the potential effects of CFs in the following 
health problems?”). Moreover, five closed multiple-choice 
multiple answers explored the ethical implications perceived 
in adopting CFs (e.g. “The use of CFs for therapeutic 
purposes can be considered ethically acceptable when….”), 
communication implications about CFs (“How do you 
communicate to the patient the use of CFs at the end of 
treatment?’), the circumstances under which they are applied 
(“Under what circumstances would you use CFs?”), and the 
possible mechanisms of action (“What mechanism of action 
can explain the effect of CFs?”).
Data Collection Procedure
Survey Monkey (Survey-Monkey, Palo Alto, California, 
www.surveymonkey.com) online survey tool was adopted to 
administer the questionnaire. The survey was disseminated 
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over a 12-week period between 18th May 2018 and 18th 
August 2018. Participants were contacted using the mailing 
list of the 12-outpatient private clinics (55). An email 
including the survey link (https://it.surveymonkey.com/r/
contestopazientiitalianimsk) and a brief note outlining 
a) the aim of the study, b) data handling (anonymity), c) the 
informed consent statement, and d) the invitation to complete 
the survey was distributed. More specifically, the statement 
in the email informed the recipient that, by clicking on the 
survey link, the respondents were providing their consent 
to participate in the study (55). Moreover, an operational 
definition of CFs was provided to introduce participants to 
the topic, thus avoiding misinterpretation (30, 35–39): “CFs 
represent a series of relational or environmental situations 
capable of influencing the perception of your healthcare 
condition. Examples of CFs are: the words and posture used 
by the clinician, the smells, the sounds, and the furnishing of 
the therapeutic setting” (2).
Three email reminders were sent 4 and 8 and 12 weeks after 
the initial contact to encourage those who did not take part 
in the survey to complete it. The time required to complete 
the survey was 10–15 min (12 min on average), as per the 
optimal time required to increase response rates in online 
surveys (57). Participation was voluntary, and no incentives 
were offered to participants (55). Due to forced response 
validation, participants were required to answer all questions 
to prevent missing data (58). Participants were able to review 
or change responses using a back button before getting to the 
end of the questionnaire. At the end of the survey, a summary 
of the answers was provided to the participants (55). Data were 
copied and deposited in an encrypted computer, and only the 
project leader could access information achieved in all stages 
of the study (55). Participants’ identities remained concealed 
to researchers; all data were anonymized (names and mail 
addresses) to ensure confidentiality and data protection and to 
avoid psychological harm (55).
Data Analysis
Survey data were downloaded from SurveyMonkey into .xls 
format and reviewed for data quality.
For descriptive statistics, continuous variables were 
reported using mean and standard deviation (SD). The five 
response options for the domain beliefs about CFs were 
also analyzed with mean and SD in order to have an average 
distribution of each single belief. Dichotomous, nominal, and 
ordinal variables, coming from single answer questions, were 
described using absolute and relative frequencies. Intervals of 
the observed estimates were calculated with a 95% confidence 
level (95%CI). For the questions with multiple answers, the 
absolute and relative frequencies were calculated for each 
combination of responses given by each participant. For 
example, considering that the fields (n) asked in the domain 
“Non-ethic” were three with dichotomous responses (r), we 
did not calculate the absolute frequency of the three possible 
fields, but of their eight combinations, given by the formula r∧n, 
to better describe the groups of participants giving multiple 
answers present in the population.
The association between the individual characteristics (section 
A of the survey) and the single choice responses given in sections 
B and C of the survey was investigated with Cramer’s V, which is 
a measure of strength and direction of association derived from 
chi-square statistics, which was not considered for the analysis 
of the differences because its significance depends on the size of 
the sample. For this purpose, age was transformed into ordinal 
variables considering a decade as variable levels for the analysis 
of correlations, as described below. Only correlation values above 
the threshold of acceptance set at 0.60 were reported.
Data analysis was handled using R software (59) and the psych 
(60) and ggplot2 (61) packages.
RESULTS
Participants’ Characteristics
The majority of patients (n = 574; 51.6%; 95%CI 48.6–54.6) 
were female; their average age was 41.7 ± 15.2 years. 43.9% of 
participants (n = 488; 95%CI 40.9–46.9) were living in the North 
of Italy at the time of the survey.
Fifty point three percent of participants were high school 
graduate (n = 559; 95%CI 47.3–53.2); a large part of them were 
employed (n = 755; 67.9%; 95%CI 65.0–70.6) in intellectual, 
scientific, and highly specialized professions (n = 164; 14.7%; 
95%CI 12.7–17.0).
Participants reported musculoskeletal pain principally located 
in the cervical spine and head region (n = 258; 23.2%; 95%CI 
20.8–25.8). They had been suffering from pain for >6 months 
(n = 563; 50.6%; 95%CI 47.6–53.6) with a mean level of severity 
of 4.9 out of 10 (95%CI 4.8–5.0). The EQI presented a mean of 
0.85 out of 1 ± 0.12.
The respondents’ demographics are described in Table 1.
Clinical Vignette 1
The most frequently chosen solution to the first vignette was 
“to suggest the possibility of delivering massage if the clinical 
condition fails to improve” (n = 525; 47.2%; 95%CI 44.2–50.2). 
The least frequent answer instead was to “try to convince the 
patient of the uselessness of massage” (n = 79; 7.1%; 95%CI 5.7–
8.8). The overall overview of data is reported in Figure 1.
Clinical Vignette 2
The most frequent answer to the second vignette was “pain is not 
organic but psychological” (n = 496; 44.6%; 95%CI 41.7–47.6), 
while the least frequent one was “supporting patient determined 
improvements after treatment with sham laser (power-off)” 
(n = 99; 8.9%; 95%CI 7.3–10.8). The single items and their 
combinations are presented in Figure 2.
Definition of CFs
The majority of patients defined CFs as “an intervention without 
a specific effect for the condition being treated, but with a 
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possible unspecific effect” (n = 715; 64.3%; 95%CI 61.4–67.1). 
Instead, the minority of patients identified CFs as “a sham 
treatment used as control tests for safety and efficacy of active 
treatment” (n = 109; 9.8%; 95%CI 8.1–11.7). The remaining 
considered CFs as “a harmless or inert intervention” (n = 167; 
15.0%; 95%CI 13.0–17.3) or “an intervention that has a special 
effect through known physiological mechanisms” (n = 121; 
10.9%; 95%CI 9.1–12.9).
Beliefs
The mean score of beliefs was 2.6 out of 5 (95%CI 2.5–2.6), 
thus denoting a substantial level of belief towards CFs among 
patients. In detail, the most believed CFs were (in descending 
order): “overt therapy” (mean = 3.4; 95%CI 3.3–3.4), “empathetic 
therapeutic alliance with the patient” (mean = 3.3; 95%CI 3.2–
3.3), “verbal communication” (mean = 3.1; 95%CI 3.0–3.1), and 
“patient-centered approach” (mean = 3.1; 95%CI 3.0–3.1). The 
least believed CFs were (in descending order): “adequate design” 
(mean = 1.8; 95%CI 1.8–1.9), “uniform” (mean = 1.8; 95%CI 
1.8–1.9), and “physical contact with the patient” (mean = 1.5; 
95%CI 1.4–1.5). An overall description of beliefs towards CFs is 
presented in Table 2.
Therapeutic Effect
Patients mainly chose “physiological and psychological” 
therapeutic effects for health problems such as acute pain (n = 
640; 57.5%; 95%CI 54.6–60.5), chronic pain (n = 629; 56.6%; 
95%CI 53.6–59.5), and insomnia (n = 562; 50.5%; 95%CI 
47.6–53.5). The “psychological” effect was predominantly 
reported for emotional (n = 689; 62.0%; 95%CI 59.0–64.8) 
and cognitive disorders (n = 616; 55.4%; 95%CI 52.4–58.3) 
and oncological problems (n = 513; 46.1%; 95%CI 43.2–49.1). 
Patients identified the therapeutic effects behind several 
health conditions such as gastrointestinal (n = 451; 40.6%; 
95%CI 37.7–43.5) and cardiovascular problems (n = 405; 
36.4%; 95%CI 33.6–39.3) as “physiological.” Infectious (n = 
629; 56.6%; 95%CI 53.6–59.5), immune/allergic (n = 566; 
50.9%; 95%CI 47.9–53.9), drug, and medication addictions 
(n = 531; 47.8%; 95%CI 44.8–50.7) were selected as having “no 
benefit.” An overall report of therapeutic effects is presented 
in Table 3.
Ethical Implications
The adoption of CFs was considered ethical when “it exerts 
beneficial psychological effects” (n = 672; 60.4%; 95%CI 57.5–
63.3). In this field, the least selected answer was “the patient 
wants or expects this treatment” (n = 51; 4.6%; 95%CI 3.5–6.0). 
The detailed responses are presented in Figure 3.
The adoption of CFs was instead considered non-ethical 
when “it is based on deception” (n = 568; 51.1%; 95%CI 
48.1–54.0). Differently, the least frequent selected answer was 
when “the evidence available is insufficient” (n = 164; 14.7%; 
95%CI  12.7–17.0). The overall responses are presented in 
Figure 4.
Communication
Participants desired to be informed about the use of CFs, thus 
selecting with a higher frequency the communication “it is 
a treatment without a specific effect for your problem, but 
capable of improving your condition” (n = 512; 46.0%; 95%CI 
43.1–49.0). The least frequent chosen item was “it can help 
but you are not sure about its effect” (n = 26; 2.3%; 95%CI 
1.6–3.5). The full combinations of responses are reported in 
Figure 5.
TABLE 1 | Participant characteristics (n = 1,112).
Demographic Values 95%CI
Gender, n (%)
 Female
 Male
574 (51.6)
538 (48.4)
48.6–54.6
45.4–51.4
Years, mean (SD) 41.7 (15.2) 40.8–42.6
Italian region, n (%)
 North
 Centre
 South
488 (43.9)
323 (29)
301 (27.1)
40.9–46.9
26.4–31.8
24.5–29.8
Social status, n (%)
 Employed
 Student
 Retired
 Housewife
 Unemployed
755 (67.9)
149 (13.4)
119 (10.7)
59 (5.3)
30 (2.7)
65.0–70.6
11.5–15.6
9.0–12.7
4.1–6.8
1.9–3.9
Type of job*, n (%)
 Nothing
  Intellectual, scientific, highly specialized profession
 Trade, service
 Office workers
 Technician
 Laborer, farmer, artisan
 Unqualified profession
 Legislator, businessman, manager
 Drivers
 Military profession
357 (32.1)
164 (14.7)
162 (14.6)
139 (12.5)
96 (8.6)
94 (8.5)
36 (3.2)
25 (2.2)
24 (2.2)
15 (1.3)
29.4–34.9
12.7–17.0
12.6–16.8
10.6–14.6
7.1–10.5
6.9–10.3
2.3–4.5
1.5–3.3
1.4–3.2
0.8–2.3
Education, n (%)
 High school
 Bachelor’s degree
 Secondary school
 Master’s degree
 Primary school
 PhD
559 (50.3)
328 (29.5)
133 (12.0)
56 (5.0)
22 (1.9)
14 (1.3)
47.3–53.2
26.8–32.3
10.1–14.0
3.9–6.5
1.3–3.0
0.7–2.2
Anatomical region of pain, n (%)
 Cervical spine–head
 Lumbar spine–pelvis
 Shoulder–arm
 Knee–leg
 Ankle–foot
 Hip–thigh
 Thoracic spine–ribs
 Wrist–hand
 Elbow–forearm
 Jaw
258 (23.2)
252 (22.7)
193 (17.4)
155 (13.9)
70 (6.3)
55 (4.9)
47 (4.2)
44 (4.0)
25 (2.2)
13 (1.2)
20.8–25.8
20.2–25.3
15.2–19.7
12.0–16.1
5.0–7.9
3.8–6.4
3.1–5.6
2.9–5.3
1.5–3.3
0.6–2.0
Duration of pain, n (%)
 Over 6 months
 Less than 3 months
 From 3 to 6 months
563 (50.6)
355 (31.9)
194 (17.4)
47.6–53.6
29.2–34.8
15.3–19.8
Intensity of pain, mean (SD) 4.9 (2.1) 4.8–5.0
EQI, mean (SD) 0.85 (0.12) 0.85–0.86
n, number of participants; %, percentage; SD, standard deviation; 95%CI, 95% 
confidence interval; >, more; visual analog scale, visual; EQI, EuroQol Index.
*According to “Nomenclature and classification of work” provided by ISTAT http://
professioni.istat.it/sistemainformativoprofessioni/cp2011/
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FIGURE 2 | Percentages of responses for clinical vignette 2. (A) the positive attention of the healthcare team leads to decreased pain; (B) pain is not organic but 
psychological; (C) the patient is very suggestible; (D) the supporting patient saw an improvement after treatment with laser switched off.
FIGURE 1 | Percentages of responses for clinical vignette 1. (A) deliver massage; (B) tell the patient that low back pain would resolve itself in a few days; (C) suggest 
the possibility of delivering massage if the clinical condition fails to improve; (D) advise a different treatment commonly used for low back pain; (E) try to convince the 
patient of the futility of the massage.
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TABLE 2 | Beliefs regarding contextual factors (n = 1,112).
Contextual factor itemsa Likert score
mean
(95%CI)
4
n (%);
95%CI
3
n (%);
95%CI
2
n (%);
95%CI
1
n (%);
95%CI
0
n (%);
95%CI
A: Professional reputation (e.g. qualification, expertise) 2.1
(2.0–2.1)
70 (6.3); 
5.0–7.9
266 (23.9); 
21.5– 26.6
513 (46.1); 
43.2–49.1
192 (17.3); 
15.1–19.6
71 (6.4); 
5.0–8.0
A: Uniform (e.g. white coat) 1.8
(1.8–1.9)
65 (5.8);
4.6–7.4
229 (20.6)
18.3–23.1
431 (38.8);
35.9–41.7
241 (21.7); 
19.3–24.2
146 (13.1);
11.2–15.3
A: Positive attitudes and behavior (e.g. towards a 
patient’s dysfunctions)
2.7
(2.6–2.7)
156 (14.0)
12.1–16.2
577 (51.9)
48.9–54.9
276 (24.8);
22.3–27.5
78 (7.0);
5.6–8.7
25 (2.2);
1.5–3.4
B: Patient’s expectation and preference (e.g. towards a 
treatment)
2.2
(2.2–2.3)
97 (8.7);
7.2–10.6
408 (36.7);
33.9–39.6
326 (29.3);
26.7–32.1
210 (18.9); 
16.7–21.3
71 (6.4);
5.1–8.0
B: Patient’s previous experience (e.g. towards a 
treatment)
2.7
(2.7–2.8)
168 (15.1);
13.1–17.4
586 (52.7);
49.7–55.7
272 (24.5); 
22.0–27.1
64 (5.8);
4.5–7.3
22 (2.0);
1.3–3.0
C: Verbal communication (e.g. positive messages 
associated with the treatment)
3.1
(3.0–3.1)
334 (30.0);
27.4–32.8
582 (52.3);
49.3–55.3
151 (13.6); 
11.6–15.8
29 (2.6); 
1.8–3.8
16 (1.4);
0.9–2.4
C: Non-verbal communication (e.g. posture, gestures, eye 
contact, facial expressions)
2.9
(2.8–2.9)
251 (22.6);
20.2–25.2
572 (51.4);
48.5–54.4
205 (18.4);
16.2–20.9
62 (5.6);
4.3–7.1
22 (2.0);
1.3–3.0
C: Empathetic therapeutic alliance with the patient (e.g. 
active listening)
3.3
(3.2–3.3)
545 (49.0);
46.0–52.0
384 (34.6);
31.8–37.4
136 (12.2);
10.4–14.3
40 (3.6);
2.6–4.9
7 (0.6);
0.3–1.4
D: Overt therapy (e.g. possibility for the patient to see the 
treatment using a mirror)
3.4
(3.3–3.4)
578 (52.0);
49.0–54.9
398 (35.8);
33.0–38.7
99 (8.9);
7.3–10.8
29 (2.6);
1.8–3.8
8 (0.7); 
0.3–1.5
D: Patient-centered approach (e.g. shared-decision of 
treatment)
3.1
(3.0–3.1)
346 (31.1);
28.4–33.9
578 (52.0);
49.0–54.9
150 (13.5);
11.6–15.7
26 (2.3);
1.6–3.5
12 (1.1); 
0.6–1.9
D: Professional approach to patient (e.g. privacy, 
punctuality)
3.0
(3.0–3.1)
380 (34.2)
31.4–37.1
496 (44.6);
41.6–47.6
154 (13.8);
11.9–16.1
56 (5.0);
3.9–6.5
26 (2.3); 
1.6–3.5
D: Physical contact with the patient (e.g. touch to inform, 
assist, prepare, take care)
1.5
(1.4–1.5)
63 (5.7);
4.4–7.2
168 (5.7);
13.1–17.4
200 (18.0);
15.8–20.4
491 (44.2);
41.2–47.1
190 (17.1);
14.9–19.5
E: Comfortable setting (e.g. little noise, music, fragrances, 
temperature)
2.7
(2.6–2.7)
174 (15.6);
13.6–17.9
562 (50.5);
47.6–53.5
259 (23.3);
20.9–25.9
86 (7.7); 
6.3–9.5
31 (2.8);
1.9–4.0
E: Adequate environmental architecture (e.g. windows 
and skylights, supportive indicators)
2.3
(2.2–2.4)
120 (10.8);
9.1–12.8
338 (30.4);
27.7–33.2
456 (41.0);
38.1–44.0
151 (13.6);
11.6–15.8
47 (4.2);
3.2–5.6
E: Adequate design (e.g. decorations, ornaments and 
colors)
1.8
(1.8–1.9)
63 (5.7);
4.4–7.2
189 (17.0);
14.9–19.4
478 (43.0);
40.1–46.0
286 (25.7);
23.2–28.4
96 (8.6);
7.1–10.5
%, percentage; n, number of participants; 95%CI, 95% confidence interval; 0, not at all; 1, few; 2, enough; 3, much; 4, a lot of; A, physical therapist domain; B, patient domain; 
C, physical therapist–patient relationship domain; D, therapy domain; E, healthcare setting domain.
aThe items were reported from: Testa M, Rossettini G. Enhance placebo, avoid nocebo: How contextual factors affect physiotherapy outcomes. Man Ther. 2016;24:65–74.
TABLE 3 | Therapeutic effect(s) of contextual factors (n = 1,112).
Clinical conditions Psychological and 
physiological
n (%); 95%CI
Psychological
n (%); 95%CI
Physiological
n (%); 95%CI
No benefit
n (%); 95%CI
Acute pain 640 (57.5); 54.6–60.5 210 (18.9); 16.6–21.3 132 (11.9); 10.1–13.9 130 (11.7); 9.9–13.8
Chronic pain 629 (56.6); 53.6–59.5 244 (21.9); 19.6–24.5 123 (11.1); 9.3–13.1 116 (10.4); 8.7–12.4
Cognitive disorder 227 (20.4); 18.1–22.9 616 (55.4); 52.4–58.3 65 (5.8); 4.6–7.4 204 (18.3); 16.1–20.8
Emotional disorder 336 (30.2); 27.5–33.0 689 (62.0); 59.0–64.8 50 (4.5); 3.4–5.9 37 (3.3); 2.4–4.6
Gastrointestinal problem 367 (33.0); 30.3–35.9 134 (12.0); 10.2–14.1 451 (40.6); 37.7–43.5 160 (14.4); 12.4–16.6
Sexual problem 505 (45.4); 42.5–48.4 336 (30.2); 27.5–33.0 99 (8.9); 7.3–10.8 172 (15.5); 13.4–17.8
Drug and medication addiction 283 (25.4); 22.9–28.1 258 (23.2); 20.8–25.8 40 (3.6); 2.6–4.9 531 (47.8); 44.8–50.7
Neurological problem 471 (42.4); 39.4–45.3 244 (21.9); 19.6–24.5 198 (17.8); 15.6–20.2 199 (17.9); 15.7–20.3
Rheumatologic problem 452 (40.6); 37.7–43.6 251 (22.6); 20.2–25.2 257 (23.1); 20.7–25.7 152 (13.7); 11.7–15.9
Immune/allergic problem 227 (20.4); 18.1–22.9 150 (13.5); 11.6–15.7 169 (15.2); 13.2–17.5 566 (50.9); 47.9–53.9
Oncological problem 310 (27.9); 25.3–30.6 513 (46.1); 43.2–49.1 74 (6.6); 5.3–8.3 215 (19.3); 17.1–21.8
Cardiovascular problem 297 (26.7); 24.1–29.4 185 (16.6); 14.5–19.0 405 (36.4); 33.6–39.3 225 (20.2); 17.9–22.7
Infectious problem 191 (17.2); 15.0–19.5 125 (11.2); 9.5–13.3 167 (15.0); 13.0–17.3 629 (56.6); 53.6–59.5
Insomnia 562 (50.5); 47.6–53.5 413 (37.1); 34.3–40.1 50 (4.5); 3.4–5.9 87 (7.8); 6.3–9.6
%, percentage; n, number of participants; 95%CI, 95% confidence interval.
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FIGURE 3 | Percentages of responses for the ethical use of Contextual Factors. (A) it exerts beneficial psychological effects; (B) the other therapies are over; (C) the 
patient wants or expects this treatment; (D) effectiveness shown by clinical experience.
FIGURE 4 | Percentages of responses for not-ethical use of Contextual Factors. (A) it is based on deception; (B) it undermines trust between patient and clinician; 
(C) the evidence is insufficient.
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Circumstances of CF Application 
and Mechanism of Action
As for the circumstances of CF application, the most frequent 
item was “as an adjunct to other interventions to optimize clinical 
responses” (n = 437; 39.3%; 95%CI 36.4–42.2). The least frequent 
answers were two items: “for non-specific problems” (n = 15; 1.3%; 
95%CI 0.8–2.3) and “to control pain” (n = 13; 1.2%; 95%CI 0.6–2.0). 
Globally, the combinations of responses are presented in Figure 6.
In terms of mechanism of action, patients selected “mind–body 
connections” as most frequent option (n = 413; 37.1%; 95%CI 
34.3–40.1). The least frequent answers were instead “natural 
history of disease” (n = 14; 1.3%; 95%CI 0.7–2.2) and “spiritual 
energies” (n = 10; 0.9%; 95%CI 0.5–1.7) as reported in Figure 7.
Correlation between Variables
The strength of association was considered weak with a Cramer’s V 
lower than the established threshold (Cramer’s V < 0.60) for all the 
correlations, such as between the characteristics reported in Table 1 
(gender, age, Italian region, social status, type of job, education, 
anatomical region of pain, duration of pain, intensity of pain, EQI) 
and the responses given in sections B and C of the survey.
DISCUSSION
To the best of our knowledge, this is the first research investigating 
the awareness of Italian patients about the therapeutic effect of CFs 
on musculoskeletal pain. The main findings of our study suggest 
that patients: a) conceptualized CFs as an intervention with an 
unspecific effect; b) believed in the clinical effectiveness of CFs; 
c) identified several possible therapeutic effects of CFs for various 
health problems; d) considered the use of CFs to stimulate beneficial 
psychological effects as ethically correct; e) saw as non-ethical the 
deceptive adoption of CFs; f) desired transparent information 
about CFs; g) recognized the application CFs as an adjunct to 
other interventions to optimize clinical responses; and h) proposed 
mind–body connection as a principal mechanism of action of CFs.
Therefore, according to our and former findings, it is 
recommended to extend the consideration of CFs in clinical 
policies and research designs, as they are also a patients’ perspective 
expression, and not only a significant contribution to the 
therapeutic outcome from clinicians’ point of view (18, 21, 25, 26, 
29, 34). Namely, if patients present an adequate knowledge of CFs, 
their implementation can be ethically acceptable by clinicians and 
researchers. On the contrary, if patients report a misconception 
about CFs, clinicians and researchers should adequately 
reconceptualise their point of view before adopting CFs.
Responding to clinical vignette 1, about 50% of our participants 
suggested the possibility of delivering the expected intervention 
(massage) if clinical condition did not improve. As reported in 
previous qualitative researches (62, 63), patients with low back 
pain considered the fulfilment of expectation as a milestone of the 
decision-making process capable of improving clinical outcome(s) 
and adherence to treatment; therefore, clinicians should adopt it 
FIGURE 5 | Percentages of responses for communicating to patients the implications of Contextual Factors. (A) it is a treatment that can help and will not hurt; 
(B) it is an effective treatment; (C) it is a treatment without a specific effect for your problem, but capable of improving your condition; (D) it is a treatment that 
induces a psychological change; (E) it can help but you are not sure about its effect; (F) you do not receive any information.
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aimed at enhancing therapeutic responses (2). However former 
studies did not explore the ethical implications we proposed to 
patients in our survey. Our observations made clinicians aware that 
satisfying patients’ expectations cannot exceed ethical boundaries 
of professional deontology not only for their personal moral values 
but also for specific willingness of the patients. In other words, 
they desire that clinician avoids the administration of the expected 
intervention when it is detrimental or simply useless.
As resulted in clinical vignette 2, the majority of Italian patients 
considered the recovery of shoulder pain with laser switched off 
as explained by symptoms of psychological origin. In accordance 
with previous international surveys on placebo (30, 35, 36), 
participants recognized the patients’ psychological profile as an 
important predictor of placebo effects, able to explain the reduction 
in complaints (64). Therefore, clinicians should remember that 
patients are aware that their psychological condition affects their 
health status, so healthcare providers may have to weight this 
component in each healthcare interaction they have.
Our results made us consider CFs as an intervention lacking 
specificity capable of influencing patients’ clinical condition 
through an unspecific effect. This confirms the patients’ vision 
of placebo as an inert (32, 39), sham (37), fake (28) substance 
without any pharmacological active ingredient (30) rather than 
an active contextual process (25). This old conceptualization of 
placebos among patients can be the result of the patients’ socio-
cultural context (education, friends and family) (29) and of the 
external information received (books, newspapers, social media, 
and the internet) (26, 52). Routinely, clinicians should assess 
their patients’ knowledge on placebo effects and try to correct 
misconceptions and inconsistencies with the current scientific 
thinking (65), for example, by encouraging the acquisition of 
information from evidence-based websites (66).
In line with previous surveys on placebos (30, 31, 35–39), Italian 
patients believed that CFs can influence therapeutic outcome(s). 
Namely, the most believed CFs are related to the therapeutic 
encounter (e.g. empathetic therapeutic alliance, communication, 
and overt therapy); the least believed CFs concerned healthcare 
design, the clinician’s uniform and the touch. Previous surveys 
focused on evaluating patients’ given value only on a part of possible 
CFs in each study, never trying to draft an importance ranking (26, 
28, 31, 35, 37, 39). In our study, we aimed to draw up a classification, 
but this result suggests that patients assign the therapeutic value of 
CFs on a case-by-case basis. From a translational perspective, this 
finding pushes clinicians to assess patients’ beliefs about specific 
CFs in order to adopt and reinforce the CFs most believed to trigger 
placebo and to reduce nocebo effects.
Italian patients identified several therapeutic effects of CFs 
for various health problems ranging from physiological and 
psychological issues to no benefit. While in previous surveys 
the expected therapeutic effect was limited to diseases in which 
psychological influence plays an important role (pain) (30, 31, 35, 
36, 39), our participants’ responses seem to be more articulated 
FIGURE 6 | Percentages of responses for circumstances of Contextual Factors application. (A) as a result of unjustified and constant demands for healthcare 
interventions; (B) to calm down the patient; (C) when all other therapies are over; (D) in addition to other interventions to optimize clinical responses; (E) for non-
specific problems; (F) to gain time; (G) as a diagnostic tool to differentiate between psychological and physiological problems; (H) to control pain.
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and support the idea that: a) CFs do not work in all diseases; b) 
CFs can act with different therapeutic effects (e.g. physiological and 
psychological); and c) the therapeutic effect of CFs depends on the 
specific nature and the severity of the disease. This heterogeneity 
could be related to the ethno cultural background that differ between 
patients from Northern (e.g. United Kingdom) and Southern 
Europe (e.g. Italy), and between European patients compared to 
other populations from different continents, as reported in former 
surveys on placebo (67). However, our findings are not conclusive, 
requiring further studies aimed at identifying patients’ perspective 
on the therapeutic effects of CFs in different health problems.
In accordance with the position of a recent expert consensus 
on placebo and nocebo for clinical practice (24), the majority 
of Italian patients considered as ethical and acceptable the use 
of CFs as therapy enhancers when they stimulate beneficial 
psychological effects and improve patients’ symptoms. The 
pursuit of patients’ benefit, the lack of harm, the absence of 
other effective treatments, and the presence of pain or other 
conditions of suffering are other main reasons for the ethical 
implementation of placebo treatments reported in literature 
(26, 30, 32–33, 34, 36–40). On the contrary, among surveys, the 
use of placebo is considered as non-ethical when: a) it conflicts 
with available scientific evidence; b) it provides advantages to 
clinicians; c) it determines dysfunctional attachment behavior 
between clinicians and patients; d) it is harmful; or e) it worsens 
clinical outcomes (26, 32–33, 34, 36, 38, 40).
Our participants considered as non-ethical the deceptive use 
of CFs. In accordance with previous surveys on placebo (26, 33, 
34, 38, 44), deception was considered negatively as it determines a 
violation of the patients’ autonomy and right to be informed about 
the treatment delivered. Indeed, it can compromise the trust towards 
clinicians particularly when deceptive treatment resulted in negative 
outcomes (37, 39). Surprisingly, in other surveys, participants 
expressed a more tolerant opinion and considered deception 
acceptable when it helps patients to improve without damaging 
patient–clinician relationship (36, 41–43). The heterogeneity of 
these data highlights the complexity behind the ethical domain of 
CFs, thus the need for further research on the topic across countries.
As for communication, the majority of Italian patients 
desired transparent information about CFs. In line with previous 
surveys (26, 30, 37–38, 39, 44), our result confirms the need to 
notify patients without lying when they receive a non-specific 
treatment. Communication is a central aspect of the patient–
clinician relationship and constitutes one of the most important 
CFs capable of triggering placebo or nocebo response with a 
relevant effect on clinical outcomes (2). Two strategies to inform 
patients have been reported in literature: 1) a direct message 
(“this is a placebo pill”) (37–39) or 2) an indirect general message 
(“this pill has helped others in the past”) that avoids the “placebo” 
word to limit misunderstanding related to the term (26, 30). 
Nevertheless, some results of previous surveys supported the 
non-transparent use of placebo treatments (35, 38–40): some 
FIGURE 7 | Percentages of responses for Contextual Factors mechanism of action. (A) patient’s expectation; (B) conditioning; (C) suggestibility; (D) natural history 
of disease; (E) psychological factors; (F) unexplained; (G) physiological/biological factors; (H) spiritual energies; (I) mind–body connections.
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respondents claimed that a clinician should not tell patients that 
the treatment was a placebo to avoid a potential lack of benefit. 
Currently, this vision appears dated and incompatible with the 
evidence available on several health conditions such as irritable 
bowel syndrome, depression, allergic rhinitis, back pain, and 
attention deficit hyperactivity disorder (68) that report positive 
clinical effects also to open-label placebo administration.
According to a previous survey among patients with 
musculoskeletal complaints (33), in our investigation, CFs are 
mainly seen by Italian patients as additional interventions that 
can optimize clinical responses. Overall, our finding suggests 
a patient’s positive attitude towards CFs, thus stimulating their 
adoption among clinicians to boost the result of evidence-based 
interventions (2, 22).
Mind–body connection has been proposed as the main 
mechanism of action of CFs by participants, in accordance 
with previous surveys on placebo (26, 28, 30, 38). Within a 
Cartesian dualistic perspective, the power of mind is able to 
activate patients’ inner resources and capacity of self-healing, 
thus directly influencing symptoms from body (28), relegating 
to a less relevant role other mechanisms such as expectation, 
conditioning, hope, psychological (e.g. attitudes, beliefs, and 
desire), and physiological factors (e.g. real change in the brain) 
(26, 28, 29, 31, 69, 70). The future analysis about the mechanisms 
behind the clinical effectiveness of CFs represents a research 
agenda capable to enrich the knowledge of patients’ perspective 
involved in the creation of placebo/nocebo effects.
STRENGTHS AND LIMITATIONS
We have investigated for the first time the knowledge of 
CFs among Italian patients with musculoskeletal pain, thus 
expanding, also by involving a wider sample, findings of research 
in this field previously conducted in other countries (31, 33). 
Furthermore, the patients’ health status as measured with the 
EQI was similar to that of the general population (48). Compared 
to focus group methodology, the use of a questionnaire-based 
survey has contributed to expand the focus of our analysis and 
revealed the complexity behind CF construct (71). Moreover, 
the adoption of clinical vignettes helped to gradually introduce a 
potentially unfamiliar topic such as CFs to patients (26).
Despite the novelty of this study, we recognize several limitations 
that could affect our findings. First, we have recruited only 
participants from outpatient clinics, thus limiting the generalization 
of findings in different contexts (e.g. inpatient services). Second, 
although not correlated to CF knowledge in our sample, participants 
had a generally high education and work position, introducing a 
possible source of bias (38). Third, social desirability and recall bias 
could have occurred due to self-reported and retrospective nature 
of data (36, 37). Finally, the distribution of response in question with 
multiple choice (either with single or multiple answers) revealed the 
presence of different strata. Therefore, the confidence level of the 
estimate varies when the proportion of responses is different from 
the estimated 50% that occurred in non-dichotomic questions. We 
suggest using our result in future research to estimate the required 
sample size more precisely using stratified random sampling.
CONCLUSION
Italian outpatient with musculoskeletal pain reported positive 
attitudes and beliefs towards the implementation of CFs in 
clinical practice, and this may have an impact at different levels.
According to the patients’ opinion, it is ethically welcome for 
clinicians to adopt CFs as an additional treatment integrated with 
the evidence-based intervention aimed at enhancing therapeutic 
outcomes.
To support a mindful clinical use of CFs, educational courses 
should be implemented in academic curricula to expand the 
knowledge among healthcare providers.
Moreover, following the patients’ vision, policymakers and 
managers should create the conditions and the normative frame 
to ease the appropriate integration of CFs in clinical practice.
Future surveys are needed to explore how patients 
conceptualise mechanisms of actions and the role of CFs in 
different health conditions and across countries.
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